EN Archives - Page 10 of 51

Is GenAI hype dying? – Why now is the best time to build

Generative AI is a game-changer with applications across industries. Companies are actively discussing it, venture capitalists are heavily investing, and both employees and users are captivated, making it a focal point of attention. On one side, there are optimists who believe GenAI will be as revolutionary as the internet, while on the other, pessimists argue that it’s “just another fad” with no tangible value. Pragmatists are beginning to question whether the GenAI hype is fading. This piece aims to explore these perspectives.

Is Preference Alignment Always the Best Option to Enhance LLM-Based Translation? An Empirical Analysis

Neural metrics for machine translation (MT) evaluation have become increasingly prominent due to their superior correlation with human judgments compared to traditional lexical metrics

Unleashing the power of AI in Clinical Trials: Key Insights from PFIZER and ARTEFACT – AI for Health Summit

The discussion revolved around the transformative role of AI in clinical trials, supported by insights from Pfizer and Artefact, and highlighted in their collaborative white paper. It showcased concrete use cases, ecosystem mapping, and challenges to scaling AI innovations.

SANOFI, AWS, IKTOS, ELAIA and MIND GROUP at AI for Health – The generative AI revolution for drug discovery

This roundtable explored the transformative role of GenAI in drug discovery, highlighting its potential to optimize processes, accelerate timelines, and foster collaboration in the pharmaceutical industry.

ROCHE, PULSELIFE and SALESFORCE at the AI for Health Summit – Omni-channel engagement of HCPs in the Age of GenAI

The roundtable focused on the transformative potential of AI and (GenAI) in omni-channel engagement for healthcare professionals (HCPs). The discussion explored how AI reshapes interactions, drives personalized experiences, and enhances processes across clinical trials, marketing, and patient engagement.

PFIZER at the AI for Health Summit – AI: On a mission to make drug development faster and smarter

Pfizer is leveraging AI to revolutionize drug development. AI is viewed as a game-changer, impacting every stage of the pharmaceutical process, from preclinical research to patient access and manufacturing, with both operational and transformative applications.

Leaders’ POV: Accelerating drug innovation through AI at SERVIER – AI for Health Summit

Servier has approached AI adoption in two phases. Initially, an opportunistic approach focused on proving AI's potential through specific use cases, especially in collaboration with R&D teams.

AMGEN, BIOGEN, Johnson & Johnson, USE&SHARE, APHP at the AI for Health Summit – Strategic vision for rare diseases

This roundtable at the AI for Health Summit 2024 focused on the use of health data and artificial intelligence to address diagnostic delays and impasses for rare diseases. With contributions from key players in research, healthcare, and industry, this discussion emphasized the need for collective mobilization to enhance the lives of over 3 million patients in France affected by rare diseases.

Revolutionizing Drug Development: Unleashing the Power of Artificial Intelligence in Clinical Trials

Read the synthesis of Artefact's report and discover insights from healthcare and pharma companies, like Servier, Pfizer, Johnson & Johnson, Google, Elaia, Inato, Klineo, Deemea, and Naaia.